Automated, contactless SLT shows safety, efficacy
Click Here to Manage Email Alerts
An automated direct transscleral selective laser trabeculoplasty device demonstrated safety and efficacy in a first-in-human study, Michal Belkin, MD, said in a presentation at the virtual American Academy of Ophthalmology annual meeting.
“The trabecular meshwork can be irradiated through the limbus without a gonioscopy lens and corneal transmission of the beam. Therefore, using our instrument, all the trabecular circumference is irradiated in about 2 seconds,” Belkin said.
The Belkin Laser EAGLE system allows for fast, accurate, automated and contactless SLT treatment, Belkin said, thus removing operator-dependent variability.
The single-center, single-arm, masked clinical study assessing safety and efficacy of the EAGLE system in patients with open-angle glaucoma and ocular hypertension investigated the procedure in 15 eyes with IOP of at least 22 mm Hg. Energy delivery ranged from 0.8 mJ to 1.4 mJ, Belkin said. Ten eyes had open-angle glaucoma, four had ocular hypertension, and one had pseudoexfoliation glaucoma.
No serious adverse events or sight-threatening adverse events were reported. In four cases, mild subconjunctival hemorrhage resolved between 1 day and 1 week with no treatment.
At 6 months in all patients, mean IOP was reduced 18.8%, and in six patients receiving the higher energy treatment, mean IOP was reduced 27.1%.
A confirmatory study is underway in Europe, Belkin said.
Collapse
Belkin M, et al. Automated translimbal selective laser trabeculoplasty: First-in-human study results. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting).
Read more about
Click Here to Manage Email Alerts